Checkpoint inhibition less toxic than antiangiogenic therapy in NSCLCMarch 30, 2018Lung CancerImmuno-oncology
HDAC inhibition may boost immune therapy efficacy in breast cancerMarch 27, 2018Immuno-oncologyBreast Cancer
Chemotherapy, metabolic pathway may affect CAR T-cell potentialMarch 22, 2018Immuno-oncologyLeukemia, Myelodysplasia, TransplantationSarcoma & GIST
Cancer groups offer guidance on immune-related adverse eventsMarch 9, 2018Immuno-oncologyPatient & Survivor CareImmunotherapy
DNA repair gene mutations predict response to anti–PD-1/PD-L1 in urothelial cancerMarch 7, 2018Immuno-oncologyGenitourinary Cancer
Avelumab safety compares with other checkpoint inhibitorsMarch 5, 2018Immuno-oncologyGynecologic CancerGenitourinary Cancer
Immunotherapy regimen influences inflammatory arthritis presentationMarch 5, 2018Patient & Survivor CareImmuno-oncologyRenal Cell CarcinomaMelanoma
Objective response rate correlates poorly with overall survival in checkpoint-inhibitor trialsFebruary 22, 2018Immuno-oncology
Study explores biological implications of MHC-II expression in tumor cellsFebruary 13, 2018Immuno-oncology
Study: Test for PD-L1 amplification in solid tumorsFebruary 7, 2018Nonmelanoma Skin CancerImmuno-oncologyCNS/Brain Cancer
New model predicts survival in atezolizumab-treated advanced urothelial carcinomaFebruary 7, 2018Immuno-oncologyGenitourinary Cancer
Pembrolizumab plus SBRT shows promise for advanced solid tumorsJanuary 27, 2018Immuno-oncologyBreast CancerLung CancerGenitourinary CancerGastroenterologyHead & Neck/Thyroid CancersGynecologic Cancer
Experimental PD-1/PARP inhibitor combo shows promise in solid tumorsJanuary 26, 2018Gynecologic CancerImmuno-oncology
